Sector revisions Attovia Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 11/09/2026 BST			5-day change	1st Jan Change
22.79 ^USD	+1.15%		-10.80%	-

09-02	Attovia Therapeutics Q2 Net Loss Widens	MT
09-02	Attovia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
ATTOVIA THERAPEUTICS, INC.	-	-	-	-	-	-	5
WUXI APPTEC CO., LTD.							18
ARGENX SE							15
INSMED INCORPORATED							22
WUXI BIOLOGICS (CAYMAN) INC.							24
BIONTECH SE							20
GENMAB A/S							15
PHARMAESSENTIA CORPORATION							8
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							18
EXELIXIS, INC.							16
SUMMIT THERAPEUTICS INC.							13
MADRIGAL PHARMACEUTICALS, INC.							16
ARROWHEAD PHARMACEUTICALS, INC.							12
AKESO, INC.							21
CYTOKINETICS, INCORPORATED							20
VAXCYTE, INC.							9
IMMUNITYBIO, INC.							4
REMEGEN CO., LTD.							16
BELITE BIO, INC							9
Average							15
Weighted average by Cap.							17

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!